A novel liposomal Clodronate depletes tumor-associated macrophages in primary and metastatic melanoma: Anti-angiogenic and anti-tumor effects

Francesca Piaggio, V. Kondylis, Fabio Pastorino, Daniela Di Paolo, Patrizia Perri, Irene Cossu, F. Schorn, Christian Marinaccio, Daniele Murgia, Antonio Daga, Federica Raggi, Monica Loi, Laura Emionite, Emanuela Ognio, M. Pasparakis, Domenico Ribatti, Mirco Ponzoni, Chiara Brignole

Research output: Contribution to journalArticle

Abstract

The depletion of tumor-associated macrophages (TAMs), involved in different stages of cancer development and progression, is an appealing strategy in cancer therapy. Wedeveloped novel Clodronate-containing liposomes (Clo-Lipo-DOTAP) presenting physicochemical properties (size distribution, polydispersity index and Z-potential) suited for safe storage and injections. In vitro, Clo-Lipo-DOTAP inhibited proliferation, reduced viability and induced apoptosis of a macrophage-like cell line in a dose- and time-dependent manner. In proof of functionality experiments, Clo-Lipo-DOTAP depleted macrophages in a genetic mouse model of chronic hepatitis and hepatocellular carcinoma leading to a significant reduction of F4/80-positive cells in the liver and spleen of treated mice compared to PBS-treated controls. The number of granulocytes, B and T lymphocytes was not affected. In B16/F10 subcutaneous melanoma-bearing mice, Clo-Lipo-DOTAP significantly reduced the volume of primary tumors (P <0.001). Within the tumors, the expression F4/80 and a-SMA was significantly lowered. Plasma levels of IL-10, Mo KC, TNF-a, VEGF and PDGF-bb were statistically decreased. In B16/F10 lung metastatic melanoma model, treatment with Clo-Lipo-DOTAP significantly reduced the number of pulmonary nodules (P b 0.05). F4/ 80-positive cells and microvessel density were statistically decreased. In conclusion, the depletion of TAMs in primary and metastatic melanoma presents anti-tumor efficacy via inhibition of angiogenesis and modulation of inflammation related cytokines.

Original languageEnglish
Pages (from-to)165-177
Number of pages13
JournalJournal of Controlled Release
Volume223
DOIs
Publication statusPublished - Feb 10 2016

Fingerprint

Clodronic Acid
Melanoma
Macrophages
Neoplasms
Lung
Genetic Models
Chronic Hepatitis
Microvessels
Tumor Burden
Granulocytes
Liposomes
Interleukin-10
Vascular Endothelial Growth Factor A
Hepatocellular Carcinoma
B-Lymphocytes
Spleen
Cell Count
1,2-dioleoyloxy-3-(trimethylammonium)propane
Apoptosis
Cytokines

Keywords

  • Adjuvant therapy
  • Liposomal Clodronate
  • Melanoma
  • TAMs

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

A novel liposomal Clodronate depletes tumor-associated macrophages in primary and metastatic melanoma : Anti-angiogenic and anti-tumor effects. / Piaggio, Francesca; Kondylis, V.; Pastorino, Fabio; Di Paolo, Daniela; Perri, Patrizia; Cossu, Irene; Schorn, F.; Marinaccio, Christian; Murgia, Daniele; Daga, Antonio; Raggi, Federica; Loi, Monica; Emionite, Laura; Ognio, Emanuela; Pasparakis, M.; Ribatti, Domenico; Ponzoni, Mirco; Brignole, Chiara.

In: Journal of Controlled Release, Vol. 223, 10.02.2016, p. 165-177.

Research output: Contribution to journalArticle

Piaggio, Francesca ; Kondylis, V. ; Pastorino, Fabio ; Di Paolo, Daniela ; Perri, Patrizia ; Cossu, Irene ; Schorn, F. ; Marinaccio, Christian ; Murgia, Daniele ; Daga, Antonio ; Raggi, Federica ; Loi, Monica ; Emionite, Laura ; Ognio, Emanuela ; Pasparakis, M. ; Ribatti, Domenico ; Ponzoni, Mirco ; Brignole, Chiara. / A novel liposomal Clodronate depletes tumor-associated macrophages in primary and metastatic melanoma : Anti-angiogenic and anti-tumor effects. In: Journal of Controlled Release. 2016 ; Vol. 223. pp. 165-177.
@article{689d3b6430a442faa84574042179db63,
title = "A novel liposomal Clodronate depletes tumor-associated macrophages in primary and metastatic melanoma: Anti-angiogenic and anti-tumor effects",
abstract = "The depletion of tumor-associated macrophages (TAMs), involved in different stages of cancer development and progression, is an appealing strategy in cancer therapy. Wedeveloped novel Clodronate-containing liposomes (Clo-Lipo-DOTAP) presenting physicochemical properties (size distribution, polydispersity index and Z-potential) suited for safe storage and injections. In vitro, Clo-Lipo-DOTAP inhibited proliferation, reduced viability and induced apoptosis of a macrophage-like cell line in a dose- and time-dependent manner. In proof of functionality experiments, Clo-Lipo-DOTAP depleted macrophages in a genetic mouse model of chronic hepatitis and hepatocellular carcinoma leading to a significant reduction of F4/80-positive cells in the liver and spleen of treated mice compared to PBS-treated controls. The number of granulocytes, B and T lymphocytes was not affected. In B16/F10 subcutaneous melanoma-bearing mice, Clo-Lipo-DOTAP significantly reduced the volume of primary tumors (P <0.001). Within the tumors, the expression F4/80 and a-SMA was significantly lowered. Plasma levels of IL-10, Mo KC, TNF-a, VEGF and PDGF-bb were statistically decreased. In B16/F10 lung metastatic melanoma model, treatment with Clo-Lipo-DOTAP significantly reduced the number of pulmonary nodules (P b 0.05). F4/ 80-positive cells and microvessel density were statistically decreased. In conclusion, the depletion of TAMs in primary and metastatic melanoma presents anti-tumor efficacy via inhibition of angiogenesis and modulation of inflammation related cytokines.",
keywords = "Adjuvant therapy, Liposomal Clodronate, Melanoma, TAMs",
author = "Francesca Piaggio and V. Kondylis and Fabio Pastorino and {Di Paolo}, Daniela and Patrizia Perri and Irene Cossu and F. Schorn and Christian Marinaccio and Daniele Murgia and Antonio Daga and Federica Raggi and Monica Loi and Laura Emionite and Emanuela Ognio and M. Pasparakis and Domenico Ribatti and Mirco Ponzoni and Chiara Brignole",
year = "2016",
month = "2",
day = "10",
doi = "10.1016/j.jconrel.2015.12.037",
language = "English",
volume = "223",
pages = "165--177",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - A novel liposomal Clodronate depletes tumor-associated macrophages in primary and metastatic melanoma

T2 - Anti-angiogenic and anti-tumor effects

AU - Piaggio, Francesca

AU - Kondylis, V.

AU - Pastorino, Fabio

AU - Di Paolo, Daniela

AU - Perri, Patrizia

AU - Cossu, Irene

AU - Schorn, F.

AU - Marinaccio, Christian

AU - Murgia, Daniele

AU - Daga, Antonio

AU - Raggi, Federica

AU - Loi, Monica

AU - Emionite, Laura

AU - Ognio, Emanuela

AU - Pasparakis, M.

AU - Ribatti, Domenico

AU - Ponzoni, Mirco

AU - Brignole, Chiara

PY - 2016/2/10

Y1 - 2016/2/10

N2 - The depletion of tumor-associated macrophages (TAMs), involved in different stages of cancer development and progression, is an appealing strategy in cancer therapy. Wedeveloped novel Clodronate-containing liposomes (Clo-Lipo-DOTAP) presenting physicochemical properties (size distribution, polydispersity index and Z-potential) suited for safe storage and injections. In vitro, Clo-Lipo-DOTAP inhibited proliferation, reduced viability and induced apoptosis of a macrophage-like cell line in a dose- and time-dependent manner. In proof of functionality experiments, Clo-Lipo-DOTAP depleted macrophages in a genetic mouse model of chronic hepatitis and hepatocellular carcinoma leading to a significant reduction of F4/80-positive cells in the liver and spleen of treated mice compared to PBS-treated controls. The number of granulocytes, B and T lymphocytes was not affected. In B16/F10 subcutaneous melanoma-bearing mice, Clo-Lipo-DOTAP significantly reduced the volume of primary tumors (P <0.001). Within the tumors, the expression F4/80 and a-SMA was significantly lowered. Plasma levels of IL-10, Mo KC, TNF-a, VEGF and PDGF-bb were statistically decreased. In B16/F10 lung metastatic melanoma model, treatment with Clo-Lipo-DOTAP significantly reduced the number of pulmonary nodules (P b 0.05). F4/ 80-positive cells and microvessel density were statistically decreased. In conclusion, the depletion of TAMs in primary and metastatic melanoma presents anti-tumor efficacy via inhibition of angiogenesis and modulation of inflammation related cytokines.

AB - The depletion of tumor-associated macrophages (TAMs), involved in different stages of cancer development and progression, is an appealing strategy in cancer therapy. Wedeveloped novel Clodronate-containing liposomes (Clo-Lipo-DOTAP) presenting physicochemical properties (size distribution, polydispersity index and Z-potential) suited for safe storage and injections. In vitro, Clo-Lipo-DOTAP inhibited proliferation, reduced viability and induced apoptosis of a macrophage-like cell line in a dose- and time-dependent manner. In proof of functionality experiments, Clo-Lipo-DOTAP depleted macrophages in a genetic mouse model of chronic hepatitis and hepatocellular carcinoma leading to a significant reduction of F4/80-positive cells in the liver and spleen of treated mice compared to PBS-treated controls. The number of granulocytes, B and T lymphocytes was not affected. In B16/F10 subcutaneous melanoma-bearing mice, Clo-Lipo-DOTAP significantly reduced the volume of primary tumors (P <0.001). Within the tumors, the expression F4/80 and a-SMA was significantly lowered. Plasma levels of IL-10, Mo KC, TNF-a, VEGF and PDGF-bb were statistically decreased. In B16/F10 lung metastatic melanoma model, treatment with Clo-Lipo-DOTAP significantly reduced the number of pulmonary nodules (P b 0.05). F4/ 80-positive cells and microvessel density were statistically decreased. In conclusion, the depletion of TAMs in primary and metastatic melanoma presents anti-tumor efficacy via inhibition of angiogenesis and modulation of inflammation related cytokines.

KW - Adjuvant therapy

KW - Liposomal Clodronate

KW - Melanoma

KW - TAMs

UR - http://www.scopus.com/inward/record.url?scp=84953208681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953208681&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2015.12.037

DO - 10.1016/j.jconrel.2015.12.037

M3 - Article

VL - 223

SP - 165

EP - 177

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

ER -